Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 39 results for progesterone

  1. Preterm labour and birth (NG25)

    This guideline covers the care of women with a singleton pregnancy at increased risk of, or with symptoms and signs of, preterm labour (before 37 weeks), and women with a singleton pregnancy having a planned preterm birth. It aims to reduce the risks of preterm birth for the baby and describes treatments to prevent or delay early labour and birth.

  2. Ectopic pregnancy and miscarriage: diagnosis and initial management (NG126)

    This guideline covers diagnosing and managing ectopic pregnancy and miscarriage in women with complications, such as pain and bleeding, in early pregnancy (that is, up to 13 completed weeks of pregnancy). It aims to improve how early pregnancy loss is diagnosed, and the support women are given, to limit the psychological impact of their loss.

  3. Preterm labour and birth (QS135)

    This quality standard covers care for pregnant women who may be at risk of, or have symptoms and signs of, starting labour and giving birth early (preterm). It describes high-quality care in priority areas for improvement.

  4. Twin and triplet pregnancy (NG137)

    This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.

  5. Women's and reproductive health guidelines

    Preterm labour and birth - Prophylactic vaginal progesterone and prophylactic cervical cerclage Emergency cervical cerclage Timing

  6. Effectiveness of different progestogens in women at risk of miscarriage: What is the clinical and cost effectiveness of vaginal micronised progesterone versus other progesterone preparations in improving outcomes in women at risk of miscarriage?

    the clinical and cost effectiveness of vaginal micronised progesterone versus other progesterone preparations in improving...

  7. Effectiveness of progestogens in women with recurrent miscarriage: What is the clinical and cost effectiveness of progesterone for improving outcomes in women with unexplained recurrent miscarriage?

    recurrent miscarriage: What is the clinical and cost effectiveness of progesterone for improving outcomes in women with unexplained...

  8. At what gestation should treatment with prophylactic vaginal progesterone for the prevention of preterm birth be started and stopped?

    Question At what gestation should treatment with prophylactic vaginal progesterone for the prevention of preterm birth be started and...

  9. Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]

    In development [GID-TA10873] Expected publication date: TBC

  10. Does progesterone reduce the risk of preterm birth in women who have risk factors for preterm birth, but do not have a short cervix (cervical length of more than 25 mm)?

    Recommendation ID NG25/5 Question Does progesterone reduce the risk of preterm birth in women who have risk factors for preterm birth,

  11. Does progesterone reduce the risk of preterm birth in women who have a short cervix (cervical length of 25 mm or less), but do not have other risk factors for preterm birth?

    Recommendation ID NG25/6 Question Does progesterone reduce the risk of preterm birth in women who have a short cervix (cervical length

  12. Proov Confirm for ovulation confirmation (MIB322)

    NICE has developed a medtech innovation briefing (MIB) on Proov Confirm for ovulation confirmation .

  13. Effects of HRT on breast cancer risk:- What is the difference in the risk of breast cancer in menopausal women on HRT with progesterone, progestogen or selective oestrogen receptor modulators?

    difference in the risk of breast cancer in menopausal women on HRT with progesterone, progestogen or selective oestrogen receptor...

  14. Linzagolix for treating symptoms of endometriosis [ID6357]

    In development [GID-TA11376] Expected publication date: 25 June 2025